Seval Beykan Schürrle, Uta Eberlein, Catherine Ansquer, Jean-Mathieu Beauregard, Lucie Durand-Gasselin, Henning Grønbæk, Alexander Haug, Rodney J Hicks, Nat P Lenzo, Shaunak Navalkissoor, Guillaume P Nicolas, Ben Pais, Magali Volteau, Damian Wild, Alexander McEwan, Michael Lassmann
PURPOSE: To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [177 Lu]Lu-satoreotide tetraxetan in patients with advanced neuroendocrine tumours (NETs). METHODS: This study was part of a phase I/II trial of [177 Lu]Lu-satoreotide tetraxetan, administered at a median cumulative activity of 13.0 GBq over three planned cycles (median activity/cycle: 4.5 GBq), in 40 patients with progressive NETs. Organ absorbed doses were monitored at each cycle using patient-specific dosimetry; the cumulative absorbed-dose limits were set at 23...
March 26, 2024: European Journal of Nuclear Medicine and Molecular Imaging